

**Supplemental Information**


**to**

**In vivo target exploration of apidaecin based on Acquired Resistance induced by**


**Gene Overexpression (ARGO assay)**

Ken'ichiro Matsumoto<sup>1,\*</sup>, Kurato Yamazaki<sup>1</sup>, Shun Kawakami<sup>1</sup>, Daichi Miyoshi<sup>1</sup>,

Toshihiko Ooi<sup>1</sup>, Shigeki Hashimoto<sup>2</sup>, and Seiichi Taguchi<sup>1,†,\*</sup>




**Figure S1. Growth curve with different concentrations of rifampicin (A) and kanamycin (B).** (A) Black square: 0  $\mu\text{M}$ , white square: 3.1  $\mu\text{M}$ , black triangle: 6.3  $\mu\text{M}$ , white triangle: 12.5  $\mu\text{M}$ , black circle: 25  $\mu\text{M}$ , white circle: 50  $\mu\text{M}$ , cross: 100  $\mu\text{M}$ , black diamond: 500  $\mu\text{M}$ . (B) Black square: 0  $\mu\text{M}$ , white square: 12.5  $\mu\text{M}$ , black triangle: 25  $\mu\text{M}$ , white triangle: 50  $\mu\text{M}$ , black circle: 100  $\mu\text{M}$ , white circle: 200  $\mu\text{M}$ .



**Figure S2.** Acquired resistance assay induced by overexpression of target proteins. A: Cell growth of recombinant *E. coli* harboring the *fabI* gene with increasing IPTG concentration. Black line: no triclosan ( $\text{OD}_{\text{Tc}(-)}$ ). Gray line: 250 nM triclosan ( $\text{OD}_{\text{Tc}(+)}$ ). B: The degree of resistance, defined as  $\text{OD}_{\text{Tc}(+)}/\text{OD}_{\text{Tc}(-)}$ , against triclosan with FabI overexpression. C: Cell growth of *E. coli* harboring the *folA* gene. Black line: no trimethoprim. Gray line: 125  $\mu\text{M}$  trimethoprim. D: The degree of resistance against trimethoprim.




**Figure S3. Reproduction of immunoblot result in Figure 4.** Experimental conditions are identical to those used in Figure 4. Lanes 2, 3 and 4: MG1655(*lacZ*-UAA), 5, 6 and 7: MG1655(*lacZ*-UGA), and 8, 9 and 10: MG1655(*lacZ*-UAG). Lanes 3, 6, and 9: 250  $\mu$ M apidaecin was added. Lanes 4, 7 and 10: 500  $\mu$ M apidaecin was added. The amount of protein was normalized to the OD of the cells.



**Figure S4. Construction diagram of recombinant *E. coli* possessing altered *lacZ***

**stop codons.** FRT: Flippase recognition target.



**Figure S5. Whole membrane image of immunoblot analysis using anti-His-tag antibody in Figure 3C.** Lanes No. 1 to 9 corresponded to IPTG concentration of 0 to 1000 in Figure 3b, respectively. M: size marker. Some of the His-tagged standard proteins acted as a positive control of immunodetection. Red color indicates overexposure that did not influence the detection of His-tagged PrfA.